

3D

CELL-BASED BIOSENSORS IN DRUG DISCOVERY PROGRAMS

Microtissue Engineering for
High-Throughput Screening

WILLIAM S. KISAALITA



3D CELL-BASED BIOSENSORS IN DRUG DISCOVERY PROGRAMS

Microtissue Engineering for
High Throughput Screening

3D CELL-BASED BIOSENSORS IN DRUG DISCOVERY PROGRAMS

Microtissue Engineering for
High Throughput Screening

WILLIAM S. KISAALITA



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2010 by Taylor and Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed in the United States of America on acid-free paper
10 9 8 7 6 5 4 3 2 1

International Standard Book Number: 978-1-4200-7349-2 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Kisaalita, William Ssempe, 1953-

3D cell-based biosensors in drug discovery programs : microtissue engineering for high throughput screening / William S. Kisaalita.
p. ; cm.

Includes bibliographical references and index.

Summary: "This book is based upon cutting-edge research conducted in the authors lab (Cellular Bioengineering), which over the past decade has developed a number of sophisticated techniques to facilitate use of 3D cell based assays or biosensors. This book uses data from peer-reviewed publications to conclusively justify use of 3D cell cultures in cell-based biosensors (assays) for (HTS). The majority of assays performed in accelerated drug discovery processes are biochemical in nature, but there is a growing demand for live cell-based assays. Unlike biochemical ones, cellular assays are functional approximations of in vivo biological conditions and can provide more biologically relevant information"--Provided by publisher.

ISBN 978-1-4200-7349-2 (hardcover : alk. paper)

1. Pharmaceutical biotechnology. 2. Biosensors. 3. High throughput screening (Drug development) I. Title.

[DNLM: 1. Biosensing Techniques--methods. 2. Cells, Cultured. 3. Drug Discovery. QT 36 K61z 2010]

RS380.K537 2010

615'.19--dc22

2010018119

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

*To Rose, my wife, and Christine and
Christopher, my parents, without whom
this book would not be possible*

Contents

Preface.....	xv
Author	xvii

PART I Introduction

Chapter 1	Biosensors and Bioassays	3
1.1	Conventional Biosensors	3
1.2	Conventional Biosensor Applications.....	8
1.2.1	Bioprocess Monitoring and Control.....	9
1.2.2	Food Quality Control	9
1.2.3	Environmental Monitoring.....	9
1.2.4	Military Biodefense Applications	12
1.2.5	Clinical Diagnostics	13
1.3	Cell-Based Biosensors versus Cell-Based Assays (Bioassays)	13
1.4	3D Cultures.....	15
1.4.1	Two-Dimensional (2D) Culture Systems.....	15
1.4.2	3D Culture Systems.....	18
1.4.3	Tissue Engineering versus Microtissue Engineering	18
1.5	Concluding Remarks	19
	References	19
Chapter 2	Target-Driven Drug Discovery.....	23
2.1	Drug Discovery and Development	23
2.1.1	Target.....	23
2.1.2	Hit.....	23
2.1.3	Lead.....	24
2.1.4	Candidate.....	24
2.1.5	Investigational New Drug (IND) Application.....	24
2.1.6	Drug or Product.....	24
2.2	The Taxol (Paclitaxel) Discovery Case	25
2.3	The Gleevec (Imatinib Mesylate) Discovery Case.....	35
2.4	Target-Driven Drug Discovery Paradigm	43
2.4.1	Genomics and Proteomics.....	44
2.4.2	Combinatorial Chemistry.....	46
2.4.3	HTS/uHTS.....	47

2.5	The New Discovery Paradigm Promise	47
2.6	Concluding Remarks	49
	References	51

PART II 3D versus 2D Cultures

Chapter 3	Comparative Transcriptional Profiling and Proteomics.....	57
3.1	Transcriptional Profiling Studies.....	57
3.2	Comparative GO Annotation Analysis.....	60
3.3	Proteomics Studies	65
3.4	Concluding Remarks	67
	References	74
Chapter 4	Comparative Structure and Function	77
4.1	Complex Physiological Relevance.....	77
4.2	Cardiomyocyte Contractility	78
4.2.1	Cells and Scaffold	78
4.2.2	Comparative Structure	78
4.2.3	Comparative Function	79
4.2.4	HTS Application Feasibility.....	80
4.3	Liver Cell Bile Canaliculi <i>In Vitro</i>	82
4.3.1	Cells and Scaffold	82
4.3.2	Comparative Structure and Function	83
4.3.3	HTS Application Feasibility.....	84
4.4	Nerve Cell Voltage-Gated Calcium Signaling	84
4.4.1	Cells and Scaffold	84
4.4.2	Comparative Structure	86
4.4.3	Comparative Function	87
4.4.4	HTS Application Feasibility.....	89
4.5	Concluding Remarks	89
	References	90

PART III Emerging Design Principles

Chapter 5	Chemical Microenvironmental Factors.....	97
5.1	Cell Adhesion Molecules.....	97
5.1.1	Cadherins	97
5.1.2	Selectins	99
5.1.3	The Integrin Superfamily.....	101
5.1.4	The Ig-Domain-Containing Superfamily of CAMs ...	103

5.2 Short-Range Chemistry 103
 5.2.1 ECM Composition..... 104
 5.2.2 Substrate Surface Chemistry..... 108
 5.3 Long-Range Chemistry 110
 5.3.1 Cytokines, Chemokines, Hormones,
 and Growth Factors 111
 5.3.2 Matrix Metalloproteinases (MMPs)..... 112
 5.4 Concluding Remarks 112
 References 115

Chapter 6 Spatial and Temporal Microenvironmental Factors..... 121
 6.1 Nano- and Microstructured Surfaces 122
 6.2 Scaffolds 122
 6.3 Nano and Scaffold-Combined Structures..... 148
 6.4 Temporal Factor..... 148
 6.5 Concluding Remarks 153
 References 160

Chapter 7 Material Physical Property and Force
 Microenvironmental Factors..... 169
 7.1 Basics..... 169
 7.1.1 Young’s Modulus, Stiffness, and Rigidity..... 169
 7.1.2 Shear Modulus or Modulus of Rigidity..... 170
 7.1.3 Material Physical Properties Characterization..... 171
 7.1.4 Contractile Force Generation in Cells..... 177
 7.1.5 Force and Geometry Sensing 179
 7.2 Stiffness-Dependent Responses 180
 7.2.1 Biological and Nonbiological
 Materials’ Stiffness 180
 7.2.2 Stiffness-Dependent Morphology and Adhesion..... 182
 7.2.3 Stiffness-Dependent Migration 183
 7.2.4 Stiffness-Dependent Growth
 and Differentiation 185
 7.2.5 Substrate Stiffness-Dependent Cell’s
 Internal Stiffness 187
 7.3 Force-Dependent Responses 189
 7.4 Concluding Remarks 193
 References 198

Chapter 8 Proteomics as a Promising Tool in the Search
 for 3D Biomarkers 207
 8.1 Why Search for Three-Dimensionality Biomarkers?..... 207
 8.2 Cellular Adhesions 209

8.3	Signaling Pathways.....	212
8.4	Overview of Proteomics Techniques.....	213
8.4.1	Protein Separation by Two-Dimensional Polyacrylamide Gel Electrophoresis (2DE)	213
8.4.2	Peptide Detection	214
8.4.3	Protein Identification	214
8.5	Study Design and Methods.....	215
8.5.1	Addressing Low-Abundance and Poor Solubility Proteins	215
8.5.2	Biomarker Validation	216
8.6	Concluding Remarks	217
	References	217
Chapter 9	Readout Present and Near Future.....	221
9.1	Readout Present and Near Future.....	221
9.2	Fluorescence-Based Readouts	224
9.2.1	Jablonski Diagram and Fluorescence Basics	224
9.2.2	Fluorescence Readout Configurations.....	225
9.3	Bioluminescence-Based Readouts.....	230
9.4	Label-Free Biosensor Readouts.....	235
9.4.1	Impedance	235
9.4.2	Surface Plasmon Resonance.....	242
9.5	Concluding Remarks	245
	References	246
Chapter 10	Ready-to-Use Commercial 3D Plates.....	253
10.1	Introduction	253
10.2	Algimatrix™.....	254
10.2.1	Fabrication.....	254
10.2.2	Complex Physiological Relevance.....	255
10.2.3	Unique Features.....	256
10.3	Extracel™.....	257
10.3.1	Synthesis.....	257
10.3.2	Complex Physiological Relevance.....	257
10.3.3	Unique Features.....	257
10.4	Ultra-Web™.....	259
10.4.1	Fabrication.....	260
10.4.2	Complex Physiological Relevance.....	260
10.4.3	Unique Features.....	261
10.5	Market Opportunities	262
10.5.1	The Opportunity.....	262
10.5.2	Potential Customers.....	262
10.5.3	Market Size	263

10.5.4 Market Size Estimation	263
10.6 Concluding Remarks	264
References	265

PART IV Technology Deployment Challenges and Opportunities

Chapter 11 Challenges to Adopting 3D Cultures in HTS Programs	269
11.1 Typical HTS Laboratory and Assay Configurations	269
11.2 Just-in-Time Reagents Provision Model	274
11.3 Limited Value-Addition from 3D Culture Physiological Relevance: Transepithelium Drug Transport and Induction of Drug Metabolizing Enzyme Cases	276
11.3.1 Transepithelium Drug Transport: Caco-2 Assay	276
11.3.2 Induction of Drug Metabolizing Enzymes: Hepatocyte Assays	283
11.4 Paucity of Conclusive Support of 3D Culture Superiority	283
References	285
Chapter 12 Cases for 3D Cultures in Drug Discovery.....	289
12.1 Three Cases	289
12.2 The β 1-Integrin Monoclonal Antibody Case.....	289
12.2.1 Integrins	289
12.2.2 Monoclonal Antibodies	290
12.2.3 Experimental System: Breast Cancer Cells in Matrigel.....	293
12.2.4 Treatment with β 1-Integrin Inhibitory Antibody Reduced Malignancy in <i>In Vitro</i> -3D and <i>In Vivo</i> , but Not in <i>In Vitro</i> -2D Systems	293
12.3 The Matrix Metalloproteinase Inhibitors Case	294
12.3.1 Extracellular Matrix Metalloproteinases (MMPs).....	294
12.3.2 MMP Inhibitors (MMPi).....	295
12.3.3 Experimental System: Fibrosarcoma Cells in Collagen Gels.....	295
12.3.4 Treatment with Pericellular Proteolysis Inhibitors in 3D Cultures and <i>In Vivo</i> Did Not Prevent Cell Migration or Metastasis	296
12.4 Resistance to the Chemotherapeutic Agents Case	297
12.4.1 Experimental System: Multicellular Tumor Spheroid (MCTS).....	297

12.4.2	MCTS More Accurately Approximate <i>In Vivo</i> Resistance to Chemotherapeutic Agents	298
12.5	Concluding Remarks	300
	References	301
Chapter 13	Ideal Case Study Design	307
13.1	Rationale for the Case Study	307
13.2	Why Hepatotoxicity?	308
13.2.1	Morphology of the Liver	308
13.2.2	What Is Hepatotoxicity?	308
13.3	Hepatotoxicity and hESC-Derived Hepatocyte-Like Cells	310
13.3.1	Two Reasons Why IADRs Have Attracted Proposed Studies	310
13.3.2	IADRs and Mitochondrial Inner Transmembrane Potential ($\Delta\Psi_m$)	314
13.4	Study Design and Methods	317
13.4.1	Experimental Design and Rationale	317
13.4.2	Cell Culture and Drug Exposure	318
13.4.3	Expression of Drug-Metabolizing Enzymes	318
13.4.4	Alanine Aminotransferase (ATL) Activity Assay	318
13.4.5	Mitochondrial Membrane Potential ($\Delta\Psi_m$) Measurement	318
13.5	Analysis and Expected Results	319
13.5.1	Quality Assessment of HTS Assays	319
13.5.2	Expected Results	319
13.5.3	Potential Pitfalls	320
	References	320
Appendix A	Patents for 3D Scaffolds	323
	References	328
Appendix B	Current Drug Targets	331
Appendix C	Popular Cell Lines in Drug Discovery	357
C1	HEK 293	357
C1.1	Background	357
C1.2	Morphology and Ploidy	358
C2	CHO	358
C2.1	Background	358
C2.2	Morphology and Ploidy	358

C3	HeLa	358
	C3.1 Background	358
	C3.2 Morphology and Ploidy	359
C4	HepG2.....	359
	C4.1 Background	359
	C4.2 Morphology and Ploidy	360
C5	U2OS	360
	C5.1 Background	360
	C5.2 Morphology and Ploidy	360
C6	COS-7/CV-1.....	360
	C6.1 Background	360
	C6.2 Morphology and Ploidy	361
	References	361
Appendix D	Stem Cells in Drug Discovery.....	363
	References	368
Index.....		373
Company Index		385

Preface

The idea for this project was planted during the 2007 Annual Society of Biomaterials Meeting in Chicago by an individual who at that time was with an HTS lab for a major pharmaceutical company. This individual, after visiting three posters from my research group on 3D cell-based biosensors, mused that, “it would be very helpful if a book was available that would integrate the knowledge bases critical to serious consideration of 3D cell-based systems in a discovery program and especially if this book would provide evidence that such systems have the potential to lower the discovery cost.” I thought deeply about what this individual said and the next day I ran the project idea by Michael Slaughter (an executive editor with Taylor & Francis) who was also at the meeting at the exhibitor stand. Michael suggested that I send him a proposal, which I did. To test the project idea, I offered a one-semester hour seminar at my institution that fall, which attracted nine graduate students with research interests in bioengineering, drug discovery, and bionanotechnology. At the end of the semester, the students were unanimous about developing a full 3-hour course on the subject, which I am currently teaching every fall of odd years.

This book is intended to serve as a catalyst for the widespread adoption of 3D cell-based systems. In addition to pharmaceutical and biopharmaceutical industry bioengineers and bioscientists involved in HTS, the book should be of value to those outside the industry with interest in tissue engineering and/or cell-based biosensors. It has been written to provide the latest—from theory to practice—on the challenges and opportunities for incorporating 3D cell-based biosensors or assays in drug discovery programs. Furthermore, the book provides evidence in support of embracing 3D cell-based systems. It goes to the root of the issue, first by comparing 2D and 3D culture from genomic to functional levels, establishing the 3D cell-based biosensor physiological relevance. Second, the bioengineering principles behind successful 3D cell-based biosensor systems are assembled in one place. Third, the challenges and opportunities for incorporating 3D cell-based biosensors or cultures in current discovery and preclinical development programs are addressed. The book will also be useful as a reference in graduate courses on biosensors and biotechnology. To maintain a broad appeal for the book, the advanced mathematical treatment I am using in my class in several chapters has been left out or kept to a minimum.

As in any book written for an audience from several disciplines, the coverage may be mundane in some areas while adequate in others, depending on the reader’s background. For this I apologize in advance. I also apologize to authors whose works may not have been cited. It has been difficult to exhaustively cite all important works and at the same time meet the publisher’s page limit for the project.

A number of individuals deserve acknowledging for their invaluable help. First, I express my gratitude to my college at the University of Georgia for unwavering support. Second, I thank the graduate students who enthusiastically participated in the class, offering to test the material contained herein. I am especially grateful to

the students in my research group: Yinzhe Lai, Ke Cheng, Lina Wang, Amish Asthena, and Angela Zachman who have contributed to this effort in more ways than I can thank them. Special thanks go to Yinzhi Lai, who in addition prepared/assembled the majority of the figures. Finally, I am grateful to my family for their patience and support of my seeming obsession with this project.

William S. Kisaalita

Author



William S. Kisaalita, PhD, is professor and former coordinator of graduate engineering programs at the University of Georgia, where he also directs the Cellular Bioengineering Laboratory. The main research focus of his laboratory is cell-surface interactions with applications in cell-based biosensing in drug discovery. He has published more than 80 peer reviewed and trade press papers and made more than 100 poster and podium presentations. He has received numerous instructional awards including membership in the University of Georgia Teaching Academy. He is a member of ACS, AAAS, ASEE, and SBS. Dr. Kisaalita serves on the editorial boards of *The Open Biotechnology Journal* and *The Journal of Community Engagement and Scholarship*.

torial boards of *The Open Biotechnology Journal* and *The Journal of Community Engagement and Scholarship*.